31-45 of 92
Severity Assessment: Can You Pin the Stage on the Patient?
MinuteCE®Severity Assessment: Can You Pin the Stage on the Patient?
Jennifer Geremia, PA-C
Brooke Hodnick, PA-C, MPAS
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
CME/CETreating MASH With Compensated Cirrhosis: A Serious Unmet Need
Naim Alkhouri, MD, FAASLD, DABOM
Robert Brown Jr, MD, MPH
Steven Flamm, MD
The Clinical Spectrum of Hepatic Encephalopathy
MinuteCE®The Clinical Spectrum of Hepatic Encephalopathy
Robert Brown Jr, MD, MPH
Steven Flamm, MD
Hepatic Encephalopathy: Unmet Therapeutic Needs
MinuteCE®Hepatic Encephalopathy: Unmet Therapeutic Needs
Robert Brown Jr, MD, MPH
Steven Flamm, MD
Robert S. Brown, Jr., MD, MPH
Steven Flamm, MD
- advertisement
Diagnosing Minimal Hepatic Encephalopathy: There's an App for That?
MinuteCE®Diagnosing Minimal Hepatic Encephalopathy: There's an App for That?
Robert Brown Jr, MD, MPH
Steven Flamm, MD
Advances in the Treatment of Hepatic Encephalopathy
MinuteCE®Advances in the Treatment of Hepatic Encephalopathy
Robert Brown Jr, MD, MPH
Steven Flamm, MD
Robert Brown Jr, MD, MPH
Steven Flamm, MD
Robert Brown Jr, MD, MPH
Steven Flamm, MD
Hepatic Encephalopathy: What's Sarcopenia Got to Do With It?
MinuteCE®Hepatic Encephalopathy: What's Sarcopenia Got to Do With It?
Robert Brown Jr, MD, MPH
Steven Flamm, MD
You Can’t Diagnose MHE Unless You Diagnose Cirrhosis
MinuteCE®You Can’t Diagnose MHE Unless You Diagnose Cirrhosis
Robert Brown Jr, MD, MPH
Steven Flamm, MD
- advertisement
Diagnosing and Treating IBS: It Begins With One Simple Question
CME/CE Broadcast ReplayDiagnosing and Treating IBS: It Begins With One Simple Question
Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
Kimberly D. Orleck, PA-C
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
MinuteCE®Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
